Xilio therapeutics announces inducement grant under nasdaq listing rule 5635(c)(4)

Waltham, mass., jan. 17, 2025 (globe newswire) -- xilio therapeutics, inc. (nasdaq: xlo), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective january 1, 2025, the company granted a non-qualified stock option to purchase 60,000 shares of its common stock to one new employee under xilio therapeutics' 2022 inducement stock incentive plan.
NDAQ Ratings Summary
NDAQ Quant Ranking